EUVIMEDEUVIMED entdecken
Crossref

Correlation between E ‐cadherin/β‐catenin, Vimentin expression, clinicopathologic features and drug resistance prediction in naïve prostate cancer: A molecular and clinical study

Rahma Said iD, Javier Hernández-Losa, Amine Derouiche, Teresa Moline, Rosa Somoza Lopez de Haro, Skander Zouari, Ahlem Blel, Soumaya Rammeh, Slah Ouerhani

genesis · 2024

DOI: 10.1002/dvg.23543 ↗

Kurz gefasst

Fachartikel in der Zeitschrift genesis, 2024. Verfasst von Rahma Said und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical and Biological Engineering, Laboratory of Protein Engineering and Bio-active Molecules, National Institute of Applied Science …. Hauptthemen laut MEDLINE: beta Catenin, Prostatic Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although epithelial–mesenchymal markers play an important role in prostate cancer (PC), further research is needed to better understand their utility in diagnosis, cancer progression prevention, and treatment resistance prediction. Our study included 111 PC patients who underwent transurethral resection, as well as 16 healthy controls. Reverse transcription‐quantitative polymerase chain reaction (RT‐qPCR) was used to examine the expression of E‐cadherin, β‐catenin, and Vimentin. We found that E‐cadherin and β‐catenin were underexpressed in primary PC tissues. E‐cadherin expression was found to be inversely associated with prostate‐specific antigen progression (PSA‐P; serum marker of progression; p = 0.01; |r| = 0.262). Furthermore, the underexpression of two markers, E‐cadherin and β‐catenin, was found to be associated with advanced tumor stage and grade ( p < 0.05). On the other hand, Vimentin was overexpressed in PC patients with a fold change of 2.141, and it was associated with the diagnosis, prognosis, and prediction of treatment resistance to androgen deprivation therapy ( p = 0.002), abiraterone‐acid ( p = 0.001), and taxanes ( p = 0.029). Moreover, the current study highlighted that poor survival could be significantly found in patients who progressed after primary surgery, did not use drugs, and expressed these genes aberrantly. In Cox regression multivariate analysis ( p < 0.05), a positive correlation between the Vimentin marker and coronary heart disease in PC patients was identified ( p = 0.034). In summary, the present study highlights the diagnostic ( p < 0.001), prognostic ( p < 0.001), and therapeutic potential of Vimentin in primary PC ( p < 0.05), as well as its implications for cardiovascular disease. Furthermore, we confirm the potential prognostic value of E‐cadherin and β‐catenin.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

beta CateninProstatic NeoplasmsHumansMaleAndrogen AntagonistsBiomarkers, TumorCadherinsEpithelial-Mesenchymal TransitionVimentinAntigens, CD

Stichwörter der Autor:innen

E‐cadherindiagnosisdrug resistancepredictionprimary prostate cancerprognosisvimentinβ‐catenin

Substanzen

Androgen Antagonistsbeta CateninBiomarkers, TumorCadherinsVimentinVIM protein, humanCDH1 protein, humanAntigens, CD

Autor:innen und Institutionen

  • Department of Chemical and Biological Engineering, Laboratory of Protein Engineering and Bio-active Molecules, National Institute of Applied Science and Technology, University of Carthage, Tunis, Tunisia.
  • Department of Pathology, Molecular Biology Laboratory, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
  • Higher Institute of Biotechnology of Beja, University of Jendouba, Jendouba, Tunisia.
  • Urology Department, Charles Nicolle Hospital, Tunis, Tunisia.
  • Pathology Anatomy and Cytology Department, Charles Nicolle Hospital, Tunis, Tunisia.

ORCID-Profile: Rahma Said

Zitieren

APA

Said, R., Hernández-Losa, J., Derouiche, A., Moline, T., de Haro, R. S. L., Zouari, S., Blel, A., Rammeh, S., & Ouerhani, S. (2024). Correlation between E ‐cadherin/β‐catenin, Vimentin expression, clinicopathologic features and drug resistance prediction in naïve prostate cancer: A molecular and clinical study. genesis. https://doi.org/10.1002/dvg.23543

Vancouver

Said R, Hernández-Losa J, Derouiche A, Moline T, de Haro RSL, Zouari S, et al. Correlation between E ‐cadherin/β‐catenin, Vimentin expression, clinicopathologic features and drug resistance prediction in naïve prostate cancer: A molecular and clinical study. genesis. 2024. doi:10.1002/dvg.23543

BibTeX
@article{Said2024,
  author = {Said, Rahma and Hernández-Losa, Javier and Derouiche, Amine and Moline, Teresa and de Haro, Rosa Somoza Lopez and Zouari, Skander and Blel, Ahlem and Rammeh, Soumaya and Ouerhani, Slah},
  title = {Correlation between E ‐cadherin/β‐catenin, Vimentin expression, clinicopathologic features and drug resistance prediction in naïve prostate cancer: A molecular and clinical study},
  journal = {genesis},
  year = {2024},
  doi = {10.1002/dvg.23543}
}
Kostenlos starten →